INFANT'S ADVIL (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1998.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
Infant's Advil is an oral ibuprofen suspension formulation approved for pediatric fever and pain relief. It works as a cyclooxygenase inhibitor to reduce inflammation and provide antipyretic and analgesic effects. This NSAID is specifically designed for infants and young children who cannot swallow tablets or capsules.
As a legacy NSAID suspension approaching loss of exclusivity with moderate competitive pressure (30), commercial teams should expect resource reallocation and portfolio rationalization.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on INFANT'S ADVIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Infant's Advil offers minimal linked job opportunities (0 current openings), reflecting its mature, stable lifecycle and OTC market positioning. Career advancement is constrained as the product approaches loss of exclusivity, making it suitable for experienced professionals managing legacy portfolios rather than those seeking growth opportunities.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo